All News

RheumNow Podcast square

Which One is the Loneliest Number (9.27.2024)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.

Read Article
Stills,continuum

EULAR/PReS Still's Disease Management Recommendations

Jack Cush, MD

Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). 

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
myositis.jpg

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

Jack Cush, MD

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.

Read Article
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
Gottrons,mechanics

Hispanic Patients With Dermatomyositis

Jack Cush, MD

JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.

DM affects all races, but it has been suggested that racial and ethnic minority patients may have more severe disease and a different autoantibody profile. This analysis characterizes the clinical features and outcomes of DM in Hispanic and non-Hispanic patients.

Read Article
juvDM1.jpg

CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis

Jack Cush, MD

CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with an estimated incidence of 3.2 per million children per year in the United States.

Read Article
EULAR/PReS Still's Disease Management Recommendations Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and… https://t.co/JZidoWEZSq https://t.co/miwnaw5BZ3
Dr. John Cush RheumNow ( View Tweet)
Adult (133,216) vs Pediatric (955) pts on JAKi - analysis of FAERS shows both @ incr risk for infections & GI AEs. Pediatric pts had more blood and lymphatic disorders, while adults had more CNS and MSK/CTD disorders https://t.co/SKjzANYPSq https://t.co/S6JPYuvSlf

Links:

Dr. John Cush RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/4fgkNJeO4i https://t.co/Z2lDloBzrI
Dr. John Cush RheumNow ( View Tweet)
PEDIALUP registry includes 138 childhood-onset SLE (cSLE) pts.w/ 15.4 yrs median F/U, showed signif increase in SLICC-damage index (DI) scores. 34% cSLE pts had active dz w/ SLEDAI ≥6. sub-Saharan African ethnicity 7-fold incr risk of active cSLE https://t.co/iLz7DMTQuf https://t.co/tJpEvst7p4

Links:

Dr. John Cush RheumNow ( View Tweet)
Chinese study of 62 Systemic JIA pts Rx w/ IV Tocilizumab (34 12 mg/kg; 28 8 mg/kg). Wk12 87% responded (JIA ACR 30w/ no fever); Week 52 results were similar. No deaths or macrophage activation syndrome occurred. https://t.co/qGgMCt597x https://t.co/lFDxAgDHfW

Links:

Dr. John Cush RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush RheumNow ( View Tweet)
Consensus Guidelines on Pediatric Methotrexate Use MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects: -indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush RheumNow ( View Tweet)
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n

Links:

Dr. John Cush RheumNow ( View Tweet)
Karolinska genotyping study of 329 JIA pts (oligo 161, Seroneg Poly 87, Seropos poly 12, Stills 24, ERA 22, PsA 19). HLA-DRB1*08 linked to JIA total; The HLA-DRB1*11 to Oligo; ANA+ JIA linked to HLA-DRB1-DQA1-DQB1, HLA-DRB1*11, & HLA-DPB1*02 https://t.co/1yNawNTEys https://t.co/dmmlH0CvRi

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip

Links:

Dr. John Cush RheumNow ( View Tweet)
US Childrens Hosp Admission database finds 8588 kids w/ SLE & ≥ 1 hospitalization; 13% for infections, w/ Bacterial pneumonia most common. cSLE In-hospital mortality in 0.4%, but 2% for infection. Highest mortality w/ PJP (21%), fungal infx (21%) https://t.co/fmyRXagCcD https://t.co/yXDMFYhhdP

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×